MetLife SEC Filings

MetLife director Christian Stephane Mumenthaler reported a small non-derivative purchase of 7 shares of MetLife, Inc. common stock on 09/09/2025 at a price of $79.29 per share. The filing states this purchase was an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning dividends that became payable were deferred and used to acquire additional deferred shares. After the transaction the reporting person beneficially owns 924 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.

Laura J. Hay, a director of MetLife, Inc. (MET) reported a non-derivative acquisition of 26 shares of MetLife common stock executed on 09/09/2025 at a reported price of $79.29 per share. After the transaction she is shown as beneficially owning 3,727 shares directly. The filing states this transaction reflects the imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning shares that became payable were deferred and recorded as additional common stock.

This disclosure is routine for director deferred compensation arrangements and documents a small, internal equity accrual rather than an open-market purchase or sale.

MetLife director William E. Kennard reported an imputed reinvestment of dividends that resulted in the acquisition of 312 shares of MetLife common stock at an implied price of $79.29 per share on 09/09/2025. After this transaction he beneficially owns 43,918 shares, held directly and indirectly, with indirect holdings attributable to shares held in the MetLife Policyholder Trust. The filing notes the acquisition arose from the Deferred Compensation Plan for Non-Management Directors, where payable shares were deferred and reinvested.

MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.

MetLife, Inc. filed an 8-K reporting a news release dated September 2, 2025, that it will redeem all outstanding shares of its 3.850% fixed rate reset non‑cumulative preferred stock, Series G, on September 15, 2025. The filing notes the cover page interactive data is provided in Inline XBRL and is signed by Timothy J. Ring, Senior Vice President and Secretary.

MetLife, Inc. announced dividend declarations for multiple preferred stock series. The company declared a quarterly dividend of $0.35263005 per share on its floating-rate Series A preferred (with a $25 liquidation preference). It also declared a semi-annual dividend of $29.375 per share on Series D (5.875% fixed-to-floating, $1,000 liquidation preference), a quarterly dividend equal to $351.5625 per share on Series E (5.625%, $25,000 liquidation preference; $0.3515625 per depositary share representing 1/1,000th), a quarterly dividend equal to $296.875 per share on Series F (4.75%, $25,000 liquidation preference; $0.296875 per depositary share representing 1/1,000th), and a semi-annual dividend of $19.250 per share on Series G (3.850%, $1,000 liquidation preference). The release is attached as Exhibit 99.1 and incorporated by reference.

MetLife, Inc. — Schedule 13D/A (Amendment No. 102)

The Board of Directors, acting as the sole reporting person, updates its disclosure on common stock held in the MetLife Policyholder Trust formed during the 2000 demutualization. As of 31-Jul-2025 the Trust owns 108,242,821 shares, representing 16.28 % of outstanding stock. The Board possesses shared voting power over all shares but no sole voting or dispositive power; economic rights remain with policyholder beneficiaries.

The position declined by 1,161,259 shares since the 28-Apr-2025 amendment, primarily from beneficiary withdrawals, the Trust’s purchase-and-sale program and routine escheatment. No director paid consideration for the shares and no new acquisitions, sales or strategic actions are announced. Voting mechanics, beneficiary withdrawal rights and other trust provisions remain unchanged. Apart from the routine share reduction, the filing contains no material transactions or changes in corporate control intent.